main content start

MedEnrich | Página principal

Continue Watching

últimos vidéos

últimos vidéos

Brightcove Home Latest Listing

Cáncer de mama

Cáncer de mama

Brightcove Cards Listing

Cáncer de próstata

Brightcove Cards Listing

Mieloma múltiple

Mieloma múltiple

Brightcove Cards Listing

Popular en MedEnrich

Popular in Sin nombre
  • Myelodysplastic Syndromes31m 24s

    Improving Diagnosis of MDS -Innovative Solutions

    Modern Web -Based digital tools based on 10 routinely used clinical parameters and Gradient Based Model can help in non-invasive diagnosis of MDS.
    mds diagnosis web based diagnosis her2negative mbc
  • Oncospecials6m 24s

    2nd Genenration TKIs for 1st line CP-CML -Selecting Right Patients

    Deep Molecular Responses (DMR) in CML can protect from progression.2nd generation TKIs are associated with higher rates of DMR than 1st generation TKIs.
    2nd generation tki deep molecular response elts high risk e14a2 transcripts
  • Mieloma múltiple4m 12s

    Key Practice Points -Myeloma Related Renal Impairment

    In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
    myeloma renal impairment key practice points
  • nasopharyngeal carcinoma44m 35s

    Comprehensive Overview of Nasopharyngeal Carcinoma

    Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.
    nasopharyngeal carcinoma immunotherapy
  • Cancer de prostata11m 27s

    Management of Advanced Prostate Cancer: nmCRPC

    Recent advances in management of nmCRPC.
    nmcrpc
  • Mieloma múltiple7m 42s

    MRD Assesment in Multiple Myeloma -Ready for Prime Time

    Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
    minimum residual disease (mrd) mrd negativity multiple myeloma
  • Cáncer de mama8m 46s

    Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer

    Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
    anti-her2 directed therapy her2-positive metastatic breast cancer expert perspective algorithm for management of her2 positive mbc
  • Myelodysplastic Syndromes17m 59s

    Genomics of AML -Therapeutic and Prognostic Implications

    ~40% of AML patients have targetable mutations. Younger patients often have FLT3-ITD or FLT3- TKD mutation. Mutations IDH-1 , IDH-2 & t-53 mutations are more common in elderly patients.
    idh 1& 2 mutations flt3-tkd mutations bcl2 inhibtors genomics of aml
  • Cáncer de mama8m 50s

    Immunotherapy of Early Breast Cancer

    I-SPY2 clinical trial laid the foundation for Immunotherapy in Early Breast Cancer with Pembrolizumab added to Neoadjuvant Chemotherapy.
    keynote -522 immunotherapy early breast cancer
  • Mieloma múltiple7m 22s

    Using Bone Targeted Therapy in Special Situations in Multiple Myeloma

    Bone targeting agents have different toxicities and rare complications which are dependent on the exposure to the specific treatment. Watch detailed video on MedEnrich on use of bone targeted agent in Multiple Myeloma
    bisphosphonates renal insufficiency hypercalcemia
  • Seminarios web anteriores

    Seminarios web anteriores

    Webinar Cards Listing

    Artículos

    Artículos

    Medbytes Cards Listing
    Hi, can I help?
    Chat de ayudaX
    Equipo de soporte
    ¡Hola! ¿Cómo puedo ayudarlo/a hoy?
    Por favor seleccione alguna de las siguientes opciones.

    Buscar información

    Problemas con el inicio de sesión o registro

    Compartir un comentario